BY PAUL SIXPENCE

ZIMBABWE became the first site for the administration of a new investigational HIV vaccine. The first doses of the IAVI C114 clinical trial were administered in late July 2025 at the Mutala Trust clinical site in Harare, CITE reports.

“This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership,” said Dr. Tariro Makadzange, clinical trial lead, Mutala Trust.

“We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.”

The development of the vaccine is a partnership that brings together Zimbabwe’s Mutala Trust, ReiThera, the Ragon Institute, International AIDS Vaccine Initiative (IAVI) and African researchers who are co-leading every phase of the trial.

In phase one of the trial, the vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1) will be administered to 120 adults between the ages of 18 and 50 years including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). Besides Zimbabwe, two other clinical trial sites are located in Cape Town and Durban, South Africa.

Trial sites were chosen on the basis of their high HIV burden and to ensure that the vaccine candidate is tested within communities affected by the epidemic.

This phase of the trial will assess the safety and ability of the vaccine candidate to provoke an immune response in the human body in persons living with HIV and those who are HIV negative.

“The IAVI C114 trial is testing a new vaccine candidate known as GRAdHIVNE1. The trial represents the first time this vaccine is being tested in humans and is aimed at assessing the safety of the vaccine and its ability to stimulate the immune system,” said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead, IAVI.

In a statement, IAVI further advised that “trial participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses.” Results of the trial are likely to be available in 2027.

In the past, several HIV vaccine trials have been conducted but none proved effective in preventing HIV acquisition. The novelity of this vaccine candidate lies in that, it uses a harmless viral vector to deliver small parts of HIV “derived from critical structural regions of HIV that are less likely to mutate” with an expected likelihood to trigger an immune response.

“GRAdHIVNE1 uses a harmless virus (a vector for the vaccine derived from a non-replicating gorilla adenovirus) to deliver small, conserved parts of HIV (called epitopes) to the body’s immune system. These targets are derived from critical structural regions of HIV that are less likely to mutate, making them good targets for killer T cells in the immune system (CD8+ T cell responses) — a type of immune defense thought to be important for long-term protection against HIV. The viral vector was selected based on its ability to stimulate this type of response. Should the vaccine be successful in stimulating the desired response, it could be tested in future trials to assess its efficacy,” Dr. Vincent Muturi-Kioi further explained.

The initiation of this clinical trial demonstrates the power of partnerships at a time when the world is witnessing funding cuts towards global public health research. The IAVIC114 clinical trial is sponsored by IAVI. The vaccine candidate, GRAdHIVNE1, was developed by ReiThera and the Ragon Institute with funding from the GatesFoundation. African researchers will be leading

SOURCE| CITE

BY STAFF REPORTER

A Zimbabwe Republic Police (ZRP) officer appeared in court today facing charges of causing disaffection among police officers, procuring the use of a motor vehicle by fraud, and transmitting false data messages intending to cause harm.

Simbarashe Mandizvidza, an Assistant Inspector in the ZRP, was remanded in custody to Monday, when he will apply for bail.

According to the State, Mandizvidza on August 14, broadcast a video on his YouTube channel, Gondo Harishaye, claiming to be the head of the ZRP, despite knowing that Commissioner General Stephen Mutamba holds the position.

The State alleges that Mandizvidza’s actions were intended to cause disaffection among police officers, contrary to Section 30 of the Criminal Law (Codification and Reform) Act, Chapter 9:23.

Mandizvidza is also accused of procuring the use of a Ford Ranger vehicle by misrepresenting to Chief Inspector Chiteure that he had been instructed by Commissioner Makomo to use the vehicle for errands.

Furthermore, the State alleges that Mandizvidza transmitted false data messages on his YouTube channel, including claims that the ZRP Traffic section had been temporarily disbanded and that Chinese nationals must leave Zimbabwe within 48 hours.

The State indicated that it will oppose Mandizvidza’s bail application, citing the seriousness of the offenses and the need to protect the public interest.

The case continues on Monday.

BY NOKUTHABA DLAMINI 

A total of 24 people lost their lives on Zimbabwe’s roads during the 2025 Heroes and Defence Forces holidays, according to statistics released by the Zimbabwe Republic Police.

The police reported 196 road traffic accidents, 13 of which were fatal, between August 11 and 13. This represents a significant increase from the previous year’s figures, which saw 149 accidents and eight fatalities.

Reckless driving, mechanical faults, speeding, and overtaking errors were cited as major causes of the accidents.

Two major accidents occurred during the period, including a fatal crash on the Mutare-Masvingo Road that claimed the lives of six Zion Christian Church congregants. Another accident on the Bindura-Shamva Road resulted in four fatalities and 17 injuries.

The police have urged motorists to prioritize vehicle maintenance, avoid speeding and reckless overtaking, and adhere to road rules and regulations to prevent further loss of life.